Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | MITF | O75030 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KDM5A | P29375 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5189407 | 0.88 | KDM5A (0.40) | TP53ALDH1A1TSHRGLAMEN1 | |
| SCHEMBL18751640 | 0.87 | TP53 (0.51) | TP53ALDH1A1TSHRGLAMEN1 | |
| SCHEMBL2485564 | 0.86 | MEN1 (0.45) | TP53ALDH1A1TSHRGLAMEN1 | |
| SCHEMBL15295474 | 0.80 | KDM4E (0.45) | ALDH1A1MEN1KMT2AKDM4ERXFP1 | |
| SCHEMBL5785897 | 0.80 | MEN1 (0.44) | TP53ALDH1A1TSHRGLAMEN1 | |
| SCHEMBL1830325 | 0.80 | MEN1 (0.44) | TP53ALDH1A1TSHRGLAMEN1 | |
| SCHEMBL7658773 | 0.79 | TP53 (0.41) | TP53ALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL5788461 | 0.79 | MEN1 (0.40) | TP53ALDH1A1TSHRGLAMEN1 | |
| SCHEMBL15200926 | 0.79 | MEN1 (0.41) | TP53ALDH1A1TSHRGLAMEN1 | |
| SCHEMBL7559771 | 0.78 | MEN1 (0.50) | TP53ALDH1A1TSHRGLAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2234485-A1 | STABLE LAQUINIMOD PREPARATIONS | Teva Pharmaceutical Industries Ltd. (IL) | 2010-10-06 | — | — | EP | claimed |
| WO-2009082471-A1 | STABLE LAQUINIMOD PREPARATIONS | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2009-07-02 | — | — | WO | claimed |
| EP-2035001-A2 | STABLE LAQUINIMOD PREPARATIONS | Teva Pharmaceutical Industries Limited (IL) | 2009-03-18 | — | — | EP | claimed |
| WO-2007146248-A2 | STABLE LAQUINIMOD PREPARATIONS | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2007-12-21 | — | — | WO | claimed |
| EP-1224172-A1 | DRUGS FOR THE TREATMENT OF MALIGNANT TUMOURS | Active Biotech AB (SE) | 2002-07-24 | — | — | EP | claimed |
| WO-2001030758-A1 | DRUGS FOR THE TREATMENT OF MALIGNANT TUMOURS | ACTIVE BIOTECH AB (SE) | 2001-05-03 | — | — | WO | claimed |
| EP-1073639-A1 | QUINOLINE DERIVATIVES | Active Biotech AB (SE) | 2001-02-07 | — | — | EP | claimed |
| WO-1999055678-A1 | QUINOLINE DERIVATIVES | ACTIVE BIOTECH AB (SE) | 1999-11-04 | — | — | WO | claimed |
| EP-2977049-A1 | STABLE LAQUINIMOD PREPARATIONS | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2016-01-27 | — | — | EP | disclosed |
| US-8552194-B2 | Process for preparing quinoline-3-carboxamide derivatives | ACTAVIS GROUP PTC EHF (IS) | 2013-10-08 | — | — | US | disclosed |
| EP-2467372-A1 | TREATMENT OF BDNF-RELATED DISORDERS USING LAQUINIMOD | Teva Pharmaceutical Industries Ltd. (IL) | 2012-06-27 | — | — | EP | disclosed |
| EP-2035001-B1 | STABLE LAQUINIMOD PREPARATIONS | TEVA PHARMA (IL) | 2011-11-09 | — | — | EP | disclosed |
| US-20110105756-A1 | Process for Preparing Quinoline-3-Carboxamide Derivatives | ACTAVIS GROUP PTC EHF (IS) | 2011-05-05 | — | — | US | disclosed |
| WO-2011019375-A1 | TREATMENT OF BDNF-RELATED DISORDERS USING LAQUINIMOD | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2011-02-17 | — | — | WO | disclosed |
| EP-1937642-A4 | CRYSTALS OF LAQUINIMOD SODIUM, AND PROCESS FOR THE MANUFACTURE THEREOF | TEVA PHARMA (IL) | 2009-03-18 | — | — | EP | disclosed |
| EP-1937642-A2 | CRYSTALS OF LAQUINIMOD SODIUM, AND PROCESS FOR THE MANUFACTURE THEREOF | Teva Pharmaceutical Industries Limited (IL) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007146248-A2 | STABLE LAQUINIMOD PREPARATIONS | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007047863-A2 | CRYSTALS OF LAQUINIMOD SODIUM, AND PROCESS FOR THE MANUFACTURE THEREOF | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2007-04-26 | — | — | WO | disclosed |
| EP-1224172-A1 | DRUGS FOR THE TREATMENT OF MALIGNANT TUMOURS | Active Biotech AB (SE) | 2002-07-24 | — | — | EP | disclosed |
| WO-2001030758-A1 | DRUGS FOR THE TREATMENT OF MALIGNANT TUMOURS | ACTIVE BIOTECH AB (SE) | 2001-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105756-A1 | Process for Preparing Quinoline-3-Carboxamide Derivatives | MYD88, TLR7, TLR3 | TP53 1635/4885ALDH1A1 1257/4885TSHR 3321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.